LoQus23 Therapeutics
25 Nov, 2024
LoQus23 CEO David Reynolds. Courtesy – LoQus23 Therapeutics.
Based at Babraham Research Campus, the company recently closed a £35m Series A led by Dutch VC Forbion alongside existing investors DDF and Novartis Venture Fund. The proceeds will primarily be used to support the pre-clinical development and initial clinical studies of LoQus23’s lead programme, an allosteric small molecule MutSβ inhibitor, which is due to enter the clinic in 2026.
LoQus23 was founded in 2019 by Entrepreneurs in Residence at DDF Dr David Reynolds, Dr Caroline Benn, and Dr Ruth McKernan.